Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Cash & Equivalents (2016 - 2025)

INVO Fertility has reported Cash & Equivalents over the past 16 years, most recently at $355891.0 for Q3 2025.

  • Quarterly Cash & Equivalents fell 28.82% to $355891.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $355891.0 through Sep 2025, down 28.82% year-over-year, with the annual reading at $741396.0 for FY2024, 218.98% up from the prior year.
  • Cash & Equivalents was $355891.0 for Q3 2025 at INVO Fertility, down from $500000.0 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $8.4 million in Q1 2021 and troughed at $90135.0 in Q4 2022.
  • The 5-year median for Cash & Equivalents is $840407.0 (2025), against an average of $2.1 million.
  • Year-over-year, Cash & Equivalents skyrocketed 2306.64% in 2021 and then plummeted 98.41% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $5.7 million in 2021, then plummeted by 98.41% to $90135.0 in 2022, then soared by 157.86% to $232424.0 in 2023, then soared by 218.98% to $741396.0 in 2024, then tumbled by 52.0% to $355891.0 in 2025.
  • Per Business Quant, the three most recent readings for IVF's Cash & Equivalents are $355891.0 (Q3 2025), $500000.0 (Q2 2025), and $840407.0 (Q1 2025).